TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$21.7m

TScan Therapeutics Past Earnings Performance

Past criteria checks 0/6

TScan Therapeutics's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been declining at an average rate of 7.1% per year.

Key information

-22.93%

Earnings growth rate

46.07%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-7.09%
Return on equity-170.55%
Net Margin-1,655.35%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Seeking Alpha • Mar 07

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Summary Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025. Financially stable with $290.1 million in cash, TScan Therapeutics has secured a non-dilutive loan and a $30 million direct offering. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Summary TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. TCRX's potential approval for TSC-101 could tap a $100-$200 million market, making the current valuation a bargain despite inherent risks. Read the full article on Seeking Alpha
Analysis Article • Nov 06

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 26

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Summary TScan Therapeutics focuses on TCR-T therapies for cancer and autoimmune diseases, leveraging its ImmunoBank and proprietary ReceptorScan platform. TCRX’s pipeline is in the early clinical stages, with multiple near-term catalysts, including promising regulatory designations and potential partnerships. The company’s leading candidates, TSC-100 and TSC-101, target AML, MDS, and ALL, with FDA RMAT designation potentially expediting approval. TCRX seems well-capitalized, with a strong balance sheet and a cash runway of 4 years. It also appears undervalued relative to its peers. Despite its early-stage research, I believe TCRX’s innovative technology and near-term catalysts make it a speculative "buy." Read the full article on Seeking Alpha
Analysis Article • Mar 23

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

It's not a stretch to say that TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) price-to-sales (or "P/S") ratio of 18.2x...
Analysis Article • Feb 17

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics, Inc. ( NASDAQ:TCRX ) just released its latest yearly report and things are not looking great...
Seeking Alpha • Aug 10

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

TScan Therapeutics press release (NASDAQ:TCRX): Q2 GAAP EPS of -$0.63 beats by $0.13. Revenue of $4.05M (+42.6% Y/Y) beats by $1.05M.
Seeking Alpha • Jul 07

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

TScan Therapeutics (NASDAQ:TCRX) has appointed Dr. Debora Barton,  as Chief Medical Officer.  Most recently, Dr. Barton was the Chief Medical Officer at Carisma Therapeutics.  In May, TScan got FDA nod to start trial of TSC-101 in blood cancer patients undergoing cell transplant.
Analysis Article • May 22

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 17

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 18

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Revenue & Expenses Breakdown

How TScan Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:TCRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 267-118300
31 Mar 269-124310
31 Dec 2510-130320
30 Sep 258-143340
30 Jun 257-137330
31 Mar 254-131320
31 Dec 243-127300
30 Sep 249-111280
30 Jun 2412-104270
31 Mar 2415-97260
31 Dec 2321-89260
30 Sep 2317-88260
30 Jun 2316-82250
31 Mar 2317-73240
31 Dec 2214-66200
30 Sep 2213-62190
30 Jun 2212-61180
31 Mar 2211-57160
31 Dec 2110-49140
30 Sep 218-42120
30 Jun 216-34100
31 Mar 213-2980
31 Dec 201-2670

Quality Earnings: TCRX is currently unprofitable.

Growing Profit Margin: TCRX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TCRX is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.

Accelerating Growth: Unable to compare TCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).

Return on Equity

High ROE: TCRX has a negative Return on Equity (-170.55%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 11:19
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.
Christopher HowertonJefferies LLC